Market Overview

UPDATE: Deutsche Bank Reiterates Buy Rating, Raises PT on XenoPort

Related XNPT
XenoPort Reports HORIZANT Included in New Expert Recommendations on Prevention, Treatment of RLS Augmentation
Who's The Next Big Pharma Acquisition?

In a report published Friday, Deutsche Bank reiterated its Buy rating on XenoPort (NASDAQ: XNPT), and raised its price target from $10.00 to $12.00.

Deutsche Bank noted, “Maintain Buy following positive initial clinical data for XP'829. XenoPort's transporter technology platform potentially offers a deep pipeline of opportunities, including XP'986 for spasticity, XP'829 (“BG12” like compound), and recently launched Regnite (Astellas) in Japan, etc. Hence, we continue to view XenoPort as an attractive investment opportunity despite the ongoing dispute over Horizant with GSK.”

XenoPort closed on Thursday at $11.15.

Latest Ratings for XNPT

Jan 2015JefferiesMaintainsBuy
Apr 2014JefferiesInitiates Coverage onBuy
Jun 2013Morgan StanleyDowngradesEqual-weightUnderweight

View More Analyst Ratings for XNPT
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Analyst Ratings


Related Articles (XNPT)

View Comments and Join the Discussion!

Get Benzinga's Newsletters